Interferon regulatory factors (IRFs) are essential regulators of cardiometabolic diseases and represent promising therapeutic targets.
Answers are grounded in this paper and cite their sources.
IRFs may link innate immunity to cardiometabolic disease; leaves open targeted therapeutic validation.
BACKGROUND: The pathological activation of innate immune system may contribute to the development of cardiometabolic diseases. The interferon regulatory factor (IRF) family members, which are the major transcription factors in innate immune signaling, are implicated in cardiometabolic diseases. OBJECTIVE: The aim of this review is to summary the current knowledge of the biological functions of IRFs in innate immune responses and immune cell development, and highlight our contemporary understanding of the functions and molecular mechanisms of IRFs in metabolic diseases, cardiovascular remodeling, and stroke. RESULTS: IRFs are the essential regulators of cardiometabolic diseases via immune-dependent and - independent manners. CONCLUSION: IRFs signaling is the promising target to manage the initiation and progression of cardiometabolic disorders.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: